U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07004075) titled 'FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration' on June 03.
Brief Summary: An open-label, randomized, multi-center phase III clinical study: Aim to evaluate the efficacy and safety of FCN-159 monotherapy versus the treatment by investigator's choice in patients with pediatric low-grade glioma harboring KIAA1549-BRAF fusion or BRAF V600E mutation
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Low-grade Glioma
Pediatric Low-grade Gliomas
pLGG With BRAF Alteration
Intervention:
DRUG: Luvometinib
Luvometinib oral tablet
BIOLOGICAL: Chem...